













# **DAY 1 - MONDAY, OCTOBER 21<sup>ST</sup>**

#### PRE-MEETINGS & SYMPOSIA

8:00 a.m - 10:00 a.m DCVMN Executive Board/Committee meeting - by invitation only

9:00 a.m - 10:00 a.m REGISTRATION

10:00 a.m - 10:30 a.m Welcome coffee

10:30 a.m - 12:30 p.m SATELLITE WORKSHOP - for all participants / Gavea Grand Ballroom A & B

20 min each Future Vaccine Manufacturing

Hosted by Imperial College London's Future Vaccine Manufacturing Research Hub &

BactiVac

Chair: C. MacLennan (BactiVac) Co-chair: B. Pierce (FVMR)

Rapporteur: C. Wolanski (Bio-Manguinhos/Fiocruz)

Progress in novel vaccine manufacturing platforms and technology transfer

B. Pierce (FVMR)

Baculovirus expression systems for vaccine development

D. Dat (Vabiotech)

Bactivac: catalyst funding for bacterial vaccines

C. MacLennan (BactiVac)

Development of biological conjugation for vaccine production

J. Cuccui (LSHTM)

Immunogenic outer membrane proteins (OMPs) as potential sub-unit vaccines

C. López Macías (Bactivac)

Q&A and discussion

12:30 p.m - 2:00 p.m Lunch

2:00 p.m - 3:30 p.m SATELLITE SYMPOSIUM -

for all participants / Gavea Grand Ballroom

30 min each A&B

DCVMN Donor's Advisory Committee meeting - by invitation only

Responsible innovation: cost-effective manufacturing and economies of scale Hosted by DCVMN Premium Partners

Chair: T. Prusik (Temptime) Co-chair: M. Lundgren (GE) Rapporteur: A. Bowles (CHAI)

The next generation supply chain:

Sense, analyze, act T. Prusik (Temptime) Vaccine manufacturing technologies and economic considerations

M. Lundgren (GE)

Aseptic Blow-Fill-Seal Fill/Finish technology and vaccines

T. Kram (Rommelag)

3:30 p.m - 3:45 p.m Coffee Break

3:45 p.m - 5:45 p.m DCVMN GENERAL ASSEMBLY -

for DCVMN corporate members only

TIME FOR NETWORKING AND

PRIVATE MEETINGS

6:00 p.m - 8:30 p.m WELCOME RECEPTION FOR ALL REGISTERED PARTICIPANTS

# DAY 2 - TUESDAY, OCTOBER 22ND

8:30 a.m - 9:00 a.m REGISTRATION

9:00 a.m - 10:30 a.m PLENARY OPENING SESSION / GAVEA GRAND BALLROOM A&B

Chair: M. Datla, DCVMN President

15 min each Co-chair: M. Zuma, Host

Rapporteur: B. de Castro, Bio-Manguinhos/Fiocruz

Inaugural address

L. H. Mandetta, Minister of Health of Brazil

Opening address

M. Datla, DCVMN President

Opening speech

N. Trindade Lima, Fiocruz President

Inaugural speech: The roads to universal health coverage

T. Ghebreyesus, WHO Director-General (by video)

Inaugural keynote lecture: Healthy people, healthy countries

C. F. Etienne, PAHO Director

Welcome note

M. Zuma, Bio-Manguinhos/Fiocruz Director

10:30 a.m - 11:00 a.m Coffee Break

11:00 a.m - 12:30 p.m INNOVATION FOR IMMUNIZATION / GAVEA GRAND BALLROOM A&B

20 min each Inaugural keynote lectures

Chair: N. Trindade Lima (Fiocruz) Co-chair: A. Precioso (Butantan)

Rapporteur: B. de Castro (Bio-Manguinhos/Fiocruz)

The future decade of immunization

K. O'Brien - by video (WHO)

Innovation in influenza response

R. Donis (BARDA)

Expect the unexpected

F. Kristensen (CEPI)

PATH's Center for Vaccine Innovation and Access

D. Kaslow (PATH)

12:30 p.m - 2:00 p.m Lunch

2:00 p.m - 3:00 p.m PROCUREMENT AND FINANCING OF VACCINES / GAVEA GRAND BALLROOM A&B

**Keynote lectures** 

20 min each Chair: S. Prasad (Bharat)

Co-chair: J. Fitzsimmons (PAHO) Rapporteur: C. Cole (CHAI)

Challenges to increase access to vaccines in the Americas

J. Barbosa (PAHO)

Engaging industry for accessible, affordable, quality vaccines

E. Kadilli (UNICEF)

Achieving equity and sustainability goals through vaccination

S. Berkley - by video (Gavi)

3:00 p.m - 5:30 p.m VOICES & CHOICES FORUM / GAVEA GRAND BALLROOM A&B

3:00 p.m - 4:00 p.m PANEL DISCUSSION I - PUBLIC MARKET DYNAMICS

Moderator: N. Steensma (CHAI) Rapporteur: C. Cole (CHAI)

Panellists:

J. Fitzsimmons (PAHO) E. Kadilli (UNICEF)

M. Zuma (Bio-Manguinhos/Fiocruz)

S. Jadhav (SII)

D. Hein (Gavi)

4:00 p.m - 4:30 p.m Coffee Break

4:30 p.m - 5:30 p.m PANEL DISCUSSION II - ACCESS TO CAPITAL: REMOVING FINANCIAL BARRIERS FOR

INNOVATIVE MANUFACTURING IN DEVELOPING COUNTRIES

Moderator: G. Cunningham (GHIF) Rapporteur: C. Cole (CHAI)

Panellists:

J. Yip (Adjuvant Capital)

Y. Kim (RIGHT Fund)

J. Martinez (BMGF)

S. Prasad (Bharat)

P. Khoury (Ology)

5:30 p.m - 6:30 p.m DCVMN ELECTIONS -

members-only event

TIME FOR NETWORKING AND PRIVATE

**MEETINGS** 

7:00 p.m - 9:00 p.m **CULTURAL DINNER** 

sponsored by Bio-Manguinhos/Fiocruz and the Brazilian people for all participants

## DAY 3 - WEDNESDAY, OCTOBER 23RD

9:00 a.m - 10:00 a.m INNOVATIVE PARTNERSHIPS

Chair: P. Tippoo (Biovac)

15 min each Co-chair: Y. Baek (Eubiologics) Rapporteur: M. Dennehy (DCVMN)

Healthy vaccine markets: perception and reality

R. K. Suri (Panacea)

Enhanced international R&D cooperation

T. A. Wartel (IVI)

NIIMBL; The BMGF Global Health Fund

R. Prasad (BMGF)

10:00 a.m - 10:30 a.m Coffee Break

#### 10:30 a.m - 12:30 p.m GAVFA BALLROOM A

20 min each

CATALYZING PRODUCT DEVELOPMENT OF VACCINE TECHNOLOGY INNOVA-TIONS: VACCINE INNOVATION PRIORITIZATION STRATEGY (VIPS)

Chair: S. Missailidis (Bio-Manguinhos/Fiocruz)

Co-chair: D. Zehrung (PATH) Rapporteur: M. Dennehy (DCVMN)

The Alliance VIPS initiative

M. Menozzi-Arnaud (Gavi)

Prioritised innovations from the VIPS initial prioritisation

D. Kristensen (PATH)

Process for the final prioritisation phase of VIPS

B. Giersing (WHO)

Panel discussion: How the Alliance Vaccine Innovation Prioritisation Strategy may help drive vaccine delivery innovations

Moderator: D. Hein (Gavi)

Panellists:

A. Ottosen (UNICEF)

D. Kaslow (PATH)

S. Gao (Innovax)

S. Prasad (Bharat)

A. Kahn (WHO)

GAVEA BALLROOM B

**REGULATORY FORUM - IMPLEMENTING** REGULATORY CONVERGENCE

Chair: N. Dellepiane (Independent Consultant) Co-chair: S. Desai (Zydus Cadila) Rapporteur: S. Ramirez (DCVMN)

Anvisa: regulatory framework for biologics and agency modernization

B. Moreira (Anvisa)

Impact of WHO prequalification and systems on access to health

C. Rodriguez (WHO)

PAHO updates on regulatory convergence

A. Guta (PAHO)

AVAREF progress in clinical trial review and reporting standards and status of convergence for vaccine registration

D. Maiga (AVAREF/WHO AFRO)

Vaccine Safety Blueprint

P. Zuber (WHO)

12:30 p.m - 2:00 p.m Lunch

Private lunch for the newly elected and current Executive Board/Committee members

#### 2:00 p.m - 4:00 p.m FUTURE VACCINES

Chair: L. Yang (CDIBP CNBG) Co-chair: W. Meng (Sinovac) Rapporteur: B. Hayman (DCVMN)

#### Novel vectors to improve antigen expression systems

S. Gilbert (Oxford University/VaxHub)

#### RNA-based candidate vaccines

B. Pierce (FVMR)

#### Novel Shigella vaccine candidates

C. MacLennan (BMGF)

### Product development of novel Chikungunya and Zika vaccine candidates

R. Ella (Bharat)

#### Novel HPV vaccines

W. Huang (Innovax)

#### PCV13 phase III clinical trial results

Q. Zhang (Beijing Minhai Biotechnology)

#### Rabies management: Using a combination of rabies vaccine (Vaxirab-N) and a cocktail of novel monoclonal antibodies (Twinrab) for PEP

S. Kumar & K. Maithal (Zydus Cadila)

#### VACCINE MARKET INTELLIGENCE

Chair: S. ladhav (SII)

Co-Chair: T. Cernuschi (WHO) Rapporteur: S. Ramirez (DCVMN)

#### Self-procuring countries: market intelligence from WHO

T. Cernuschi (WHO)

#### Vaccine demand for UNICEF procuring countries

A. Ottosen (UNICEF)

#### PAHO work on improving access to vaccines

J. Fitzsimmons (PAHO)

#### Panel discussion: Leveraging market intelligence and global demand estimates to support DCVM investment decisions Moderator: S. Jadhav (SII)

Panellists:

T. Cernuschi (WHO)

A. Ottosen (UNICEF)

E. Baker (Gavi)

J. Fitzsimmons (PAHO)

L. Neti (Biological E)

A. Wong (Walvax)

4:00 p.m - 4:30 p.m

Coffee Break

#### 4:30 p.m - 5:30 p.m

#### CLOSING SESSION / GAVEA BALLROOM A

Chair: A. Homma (Bio-Manguinhos/Fiocruz)

Co-Chair: D. Dat (Vabiotech) Rapporteur: E. J. Hur (DCVMN)

# Closing keynote lecture: Equitable vaccine access high on the global health agenda

M. Simão (WHO)

#### Closing remarks

Host of AGM 2020

# DAY 4 - THURSDAY, OCTOBER 24TH

9:00 a.m - 12:00 a.m WHO PIP MEETING- by invitation only / Leme Room

9:00 a.m – 10:15 a.m Overview of the Pandemic Influenza Preparness (PIP) Framework

Speakers:

A. Huvos (WHO)

S. Kontic (WHO)

- Framework objectives
- Benefit sharing under the Framework (e.g. SMTA2 vaccine supply agreements)
- Requirements for supplying vaccine to WHO/UN during a pandemic

10:15 a.m - 10:30 a.m Coffee break

10:30 a.m – 12:00 p.m Preparing for deployment of pandemic influenza vaccine

Speakers:

A. Huvos (WHO)

S. Kontic (WHO) I. Ghiga (WHO)

PAHO Revolving Fund (TBD)

- Lessons learned from H1N1: Where are we now?
- Outcomes of Geneva meeting on the same topic with IFPMA
- Key priority areas/issues where WHO and industry partners could work together
- Next steps and establishing communication pathways between industry and WHO

# DAY 4 - THURSDAY, OCTOBER 24TH

8:30 a.m - 12:30 p.m OPTIONAL SITE VISIT TO FIOCRUZ FOUNDATION

8:30 a.m Bus pick up from the venue

9:30 a.m Arrival at facilities

9:40 a.m Visit

11:30 a.m End of the visit

12:30 p.m Back at the venue